Literature DB >> 15888284

Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas.

K Yamaguchi1, M Nakamura, K Shirahane, H Konomi, N Torata, N Hamasaki, M Kawakita, M Tanaka.   

Abstract

BACKGROUND: Serum carcinoembryonic antigen (highly specific) and carbohydrate antigen 19-9 (highly sensitive) have been used as tumour markers for pancreatobiliary cancers. A novel urine tumour marker, diacetylspermine, was compared with the two conventional serum tumour markers in 125 patients with pancreatobiliary diseases.
RESULTS: When the diagnosis of benign or malignant condition was examined, the sensitivity of urine diacetylspermine (75%) was higher than that of serum carcinoembryonic antigen (44%; P=0.048) and the same as that of serum carbohydrate antigen 19-9 (75%). The specificity of urine diacetylspermine (81%) was lower than that of serum CEA (92%) and as high as that of serum carbohydrate antigen 19-9 (80%). The efficiency of urine diacetylspermine (79%) was higher than that of serum carcinoembryonic antigen (74%) and the same as that of serum carbohydrate antigen 19-9 (79%).
CONCLUSION: These results suggest that urine diacetylspermine is a marker for pancreatobiliary carcinoma, which is as highly sensitive and specific as serum carbohydrate antigen 19-9.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15888284     DOI: 10.1016/j.dld.2004.10.006

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  2 in total

1.  Urinary Metabolomics to Identify a Unique Biomarker Panel for Detecting Colorectal Cancer: A Multicenter Study.

Authors:  Lu Deng; Kathleen Ismond; Zhengjun Liu; Jeremy Constable; Haili Wang; Olusegun I Alatise; Martin R Weiser; T P Kingham; David Chang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-05-31       Impact factor: 4.254

Review 2.  -The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Int J Biol Markers       Date:  2011-09-21       Impact factor: 2.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.